Forest Expects Benicar Sales To Increase With 80 Additional Sankyo Reps
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest expects sales for the antihypertensive Benicar (olmesartan) to increase due to an additional 80 reps from its co-promotion partner Sankyo
You may also be interested in...
Daiichi Sankyo Will Focus On Six Therapeutic Areas
Merger will allow the partners to increase R&D in cardiovascular, antibacterial, glucose metabolic, bone disorder, immune disorder and anti-allergy categories. As a single entity, Daiichi and Sankyo expect to increase their combined 2,200-person global sales force.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.